The most spectacular success of prime editing in eye disease therapy was restoring visual functions in a mouse model of retinitis pigmentosa through correcting the inherited missense mutation in exon 13 of the phosphodiesterase 6B (PDE6B) gene, whose product is essential for the initiation of rod phototransduction [76,77,78]. Here, PDE6B is linked to retinitis pigmentosa.